Broadview Ventures Inc’s Post

💰💲 Less than three weeks until the big day 🎅🏻 and the VC's are clearly feeling very festive as we see a resurgence in the high value deals this week. A nice early present for the fortunate biotech's who are going to be heading into 2025 with a full bank balance for their R&D spend. 🧪 Olema Oncology - $250 million equity funding and collaboration with Novartis 🦠 Nuvig Therapeutics Inc. - $161 million series B 🧬 Maze Therapeutics- $115 million series D 🩺 Antag Therapeutics - 80 million euros series A 💊 Senti Biosciences - $37.6 million equity funding #financialfridays #biotechinvestment #venturecapitalist #vcinvestment

🫀💵Great new day for the team at CorFlow as they announce €44M in new #funding toward their novel, CoFl, diagnostic and drug delivery platform for #microvascular obstruction (MVO). CorFlow’s CoFI system provides physicians with the ability to both detect and delivery therapy to life threatening MVOs in patients suffering acute #coronary events while still in the cath lab. The Series B will fund CorFlow’s MOCA II (MVO with CoFI System Assessment II) pivotal study across the US and Europe validating efficacy to diagnosis MVOs in heart attack patients post stent implementation as well as study for their adaptive therapeutic delivery platform. This latest round was co-led by Broadview Ventures Inc and Panakes Partners alongside 415 Capital, CorFlow’s initial VC investor and largest shareholder. "CorFlow’s breakthrough technology has been designed by clinicians for clinicians and we are excited to support CorFlow's mission to generate robust clinical data in order to get this much needed therapy to the patient as quickly as possible. We also are committed to supporting the emerging field of microvascular disease in general, and this oversubscribed funding round gives us options to apply the technology in new ways, and in new geographies, where patients can benefit.” - Barbara Castellano, Partner at Panakes Partners #medtechmoney #coronarydisease #venturecapital #medicalinnovation The Mullings Group

Seaport Therapeutics Raises Mega Funding Round For New Antidepressants PureTech Health (NASDAQ: PRTC) has announced that their founded entity Seaport Therapeutics has raised $225M USD in a Series B financing round. Seaport Therapeutics is developing new types of therapeutics for both major depressive disorder and generalized anxiety disorder, leveraging a proprietary technology platform that enhances oral bioavailability and reduces common side effects of traditional psychiatric drugs. What's happening, the big idea, and more: https://lnkd.in/esGVitz5 Featured | cc: Bharatt Chowrira, Eric Elenko, Robert Lyne, Charles Sherwood III, Spencer Ball, Michael Inbar, CPA, MBA, Frank Salisbury, Allison Mead Talbot, Anita Terpstra, PhD, JD, Luba Greenwood, J.D., Dr. Sven Dethlefs, Daphne Zohar, Steven Paul, Antony Loebel, Michael C. Chen, Lana Gladstein, Eric Green #biotech #healthcare #mentalhealth #innovation

💵 Iovance Biotherapeutics Stocks Drop ⬇ Yesterday saw a dip in stock prices for Iovance Biotherapeutics, Inc. However, it’s important to remember that innovation often comes with hurdles and the strides Iovance Biotherapeutics, Inc. are making in developing cutting-edge cancer therapies show promise and potential in revolutionizing the fight against cancer. Challenges are a part of any growth journey, and Iovance Biotherapeutics, Inc. is no exception. The recent financial report highlights areas to improve, but it also underscores the company's commitment to advancing healthcare. Looking forward to seeing their future successes! 💫 #Biotech #Innovation #Healthcare #Biotherapeutics

In business news, Bright Peak Therapeutics announced that it raised $90 million in a Series C financing. The round was led by Johnson & Johnson Innovation – JJDC, with participation from additional new investors Venrock, KB Investment, and Northleaf Capital Partners. Existing investors participating in the round include founding investor Versant Ventures along with Fidelity Management & Research Company, RA Capital Management, Qatar Investment Authority, Invus, Alexandria Venture Investments, and an undisclosed leading healthcare investment fund. Proceeds from the Series C financing will be used to advance BPT567 into a Phase 1/2a clinical trial and accelerate a pipeline of next-generation immunotherapies. BPT567 is a first-in-class PD1-IL18 immunoconjugate designed to provide simultaneous blockade of the PD(L)-1 checkpoint pathway and targeted delivery of IL-18 signaling. https://lnkd.in/eFurmiVb

Spoke to Cody Shandraw earlier this week about the ongoing FDA priority review for Lykos Therapeutics MDMA-assisted therapy, and the chances of it passing. He firmly believes if approved by the FDA, with a slated time period of early August, that would we could see the following .. “I think you could see a market move unlike anything for an industry throughout public markets history” Does it seem bold? Well think about what’s happened this year. atai Life Sciences $50m investment into Beckley Psytech. Cybin Inc raising $150m with a number of strategic biotech investors. MindMed and the $175m they raised after their ground breaking phase 2 results. Reunion Neuroscience raising $103m. Not to mention, Lykos raised $100m back in January. If approved, you’re only going to see the valuation of this company increase dramatically. Check our latest podcast in the comment section. Doug Drysdale Robert Barrow Payton Nyquvest Cosmo Feilding Mellen Florian Brand Christian Angermayer Lars Christian Wilde E. Matthew ("Whiz") Buckley Elemer Piros Daniel Carcillo Joe Caltabiano Rob Crocker Graham Farrell Michael Boughner Tyler Beuerlein Michael Tan Rick Doblin Michael B. Galloro, CPA Barrington Miller #psychedelics #psychedelic #psychedelicstocks #mentalhealth #stocks

Iambic Therapeutics has successfully closed a $50 million Series B extension, led by Mubadala Capital and Exor Ventures. This funding will enhance their AI-driven drug discovery efforts. The company is dedicated to transforming patient care through advanced clinical programs and a proprietary rapid design-make-test cycle, enabling swift prototyping and refinement of therapeutic strategies. Notably, they are developing HERO inhibitors, a potential breakthrough in oncology. This investment from Mubadala Capital and Exor Ventures endorses Iambic Therapeutics' direction and aspirations, accelerating their efforts to pioneer sophisticated therapies and fulfill the promise of individualized medicine. #Biotech #Funding #Innovation #AIDrugDiscovery #ClinicalAdvancement #PersonalizedMedicine #HEROinhibitors #CancerTreatment #SeriesBFunding #MubadalaCapital #ExorVentures #PatientCareTransformation #SanDiegoBiotech #TherapeuticBreakthroughs

🔬 Breaking: Genmab Acquires ProfoundBio, Signals Active M&A Strategy in Oncology Space TL;DR: Genmab strengthens oncology pipeline through strategic acquisition, with CFO indicating openness to further M&A opportunities. This move highlights a growing trend in biotech: strategic acquisitions are becoming crucial for maintaining competitive edge and accelerating innovation. The acquisition could trigger a wave of similar deals across the sector. Key Takeaways for Biotech Leaders: • Evaluate your pipeline gaps proactively • Monitor industry M&A patterns closely • Consider strategic partnerships as growth accelerators • Stay alert to emerging market opportunities 💡 Strategic Question: How is your organization positioning itself in this increasingly dynamic M&A landscape? Share your thoughts below on how this acquisition might reshape oncology development strategies. #Biotech #MergersAndAcquisitions #Oncology #BiotechStrategy #pharma #biotech #medicinetomarket

Golden Seeds is excited to welcome Divya Yerraguntla, Head of Go-To-Market at Treehill Partners for an engaging conversation with Golden Seeds member Maya Das, centered on the opportunities and challenges for angel investors in the early-stage therapeutics space.   During tomorrow's Trend Talk, Divya will share insights into what it takes to successfully bring early-stage drugs to market and the critical factors angel investors should consider in this evolving ecosystem. #angelinvesting #therapeutics #investing

Listen to our CEO's conversation to learn more about our journey and mission to map the therapeutic potential of secreted proteins and engineer them as biologics that promote tissue health function to treat chronic metabolic and muscle diseases!